MBX Biosciences, Inc.

MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders. The company's lead program, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 trials for chronic hypoparathyroidism. The company is also advancing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist in Phase 1 development for post-bariatric hypoglycemia, a complication arising from bariatric surgery. Additionally, MBX 4291, an obesity candidate, is in investigational new drug-enabling studies.

The company operates as a clinical-stage entity with no marketed products and therefore generates no product revenue. Its pipeline focuses on unmet needs in endocrine conditions and metabolic disorders, with development concentrated on injectable peptide-based therapeutics. MBX Biosciences maintains a lean operational structure with 43 full-time employees and is headquartered in Carmel, Indiana. The company was incorporated in Delaware and founded in 2018.